Baculoviral inhibitor of apoptosis family of proteins repeat-containing 5 gene methylation status in peripheral blood mononuclear cells and plasma survivin levels in patients with Behçet's disease.

Apoptosis Behçet’s disease methylation survivin

Journal

Archives of rheumatology
ISSN: 2618-6500
Titre abrégé: Arch Rheumatol
Pays: Turkey
ID NLM: 101639000

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 19 04 2020
accepted: 21 06 2020
entrez: 16 9 2021
pubmed: 17 9 2021
medline: 17 9 2021
Statut: epublish

Résumé

This study aims to evaluate the baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene methylation in the peripheral blood mononuclear cells (PBMCs) in patients with Behçet's disease (BD) compared to healthy controls and the association of survivin with BD activity. A cross-sectional study was conducted on 43 BD patients (22 males, 21 females; mean age 36.6±10.1 years; range, 18 to 66 years) and 44 age- and sex-matched healthy controls (23 males, 21 females; mean age 35.4±7.5 years; range, 18 to 61 years) between August 2019 and December 2019. Sample size was calculated guided by taking into account the difference of 1.5 units between the mean expression of BIRC5 gene in the BD and control groups, as well as considering α=0.5 and power=80%. We assessed the methylation status of the BIRC5 gene in PBMCs of BD and control groups by methylation-specific polymerase chain reaction (MS-PCR). Plasma levels of survivin were measured by enzyme- linked immunosorbent assay. Oral aphthous ulcer, genital ulcer, and skin lesions were the most common clinical manifestations in BD group. MS-PCR showed that the deoxyribonucleic acid samples of BD and control groups were not different in methylated and unmethylated areas and alleles were heterozygote. No significant difference was observed in the plasma levels of survivin in BD (98.86±25.5 pg/mL) and control (118.16±37.4 pg/mL) groups. There was no significant correlation between survivin plasma levels and BD activity. Our study did not show any evidence of association between the alteration in the BIRC5 gene methylation, survivin production, and apoptosis dysregulation in BD.

Identifiants

pubmed: 34527922
doi: 10.46497/ArchRheumatol.2021.8163
pmc: PMC8418771
doi:

Types de publication

Journal Article

Langues

eng

Pagination

185-191

Informations de copyright

Copyright © 2021, Turkish League Against Rheumatism.

Déclaration de conflit d'intérêts

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Références

Clin Lab. 2016;62(5):855-61
pubmed: 27349011
Autoimmun Rev. 2017 Aug;16(8):845-855
pubmed: 28564620
Semin Arthritis Rheum. 2012 Apr;41(5):652-7
pubmed: 22035627
Mod Rheumatol. 2019 Jul;29(4):633-639
pubmed: 29943671
Bratisl Lek Listy. 2017;118(3):164-168
pubmed: 28319413
Mediators Inflamm. 1998;7(2):111-4
pubmed: 9836498
Arthritis Rheum. 2005 Jul;52(7):2179-91
pubmed: 15986355
Adv Pharm Bull. 2020 Jun;10(2):278-283
pubmed: 32373497
Science. 1995 Mar 10;267(5203):1456-62
pubmed: 7878464
J Rheumatol. 2010 Sep;37(9):1864-70
pubmed: 20551096
Int Arch Allergy Immunol. 2002 Oct;129(2):175-80
pubmed: 12403936
J Cell Biochem. 2018 Aug;119(8):6614-6622
pubmed: 29719061
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Reumatol Clin (Engl Ed). 2020 May - Jun;16(3):229-234
pubmed: 30076035
Mediators Inflamm. 1999;8(2):101-6
pubmed: 10704147
Medicine (Baltimore). 2015 Jan;94(4):e468
pubmed: 25634192
J Cell Physiol. 2019 Nov;234(11):19440-19450
pubmed: 31020660
Ocul Immunol Inflamm. 2002 Mar;10(1):47-52
pubmed: 12461703
Int J Rheum Dis. 2014 May;17(4):430-4
pubmed: 24118939
Inflammation. 2010 Dec;33(6):381-8
pubmed: 20195727
Ocul Immunol Inflamm. 2001 Sep;9(3):185-91
pubmed: 11815887
Immun Inflamm Dis. 2019 Dec;7(4):308-317
pubmed: 31709782
J Eur Acad Dermatol Venereol. 2005 Sep;19(5):569-72
pubmed: 16164710
Rheumatology (Oxford). 2004 Jan;43(1):73-8
pubmed: 12890862
Biomed Pharmacother. 2017 Jul;91:526-533
pubmed: 28482290
Ann Rheum Dis. 2010 Apr;69(4):747-54
pubmed: 19684014
Clin Lab. 2015;61(12):1897-903
pubmed: 26882813
Front Immunol. 2019 Mar 29;10:665
pubmed: 30984205
Mod Rheumatol. 2009;19(5):536-41
pubmed: 19590934
Immunol Lett. 2018 Nov;203:15-20
pubmed: 29990515

Auteurs

Yasamin Pahlavan (Y)

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz, Iran.

Alireza Khabbazi (A)

Department of Internal Medicine, Connective Tissue Diseases Research Center, Tabriz, Iran.

Classifications MeSH